1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Mitsubishi Tanabe Pharma Development America Inc Clinical Trial

Mitsubishi Tanabe Pharma Development America Inc Europe

Back

Download Excel File

Show entries

Search:

Country/Continent	Trial Id	Start Date	Acronym	Study Title	Product Name	Primary Product	Synonym	Product Type	Biological Subtype	Industry Type	Biomarker/Moa	Disease/Indication	Therapeutic Area	Trial Status	Terminated Reason	Completion Date	Originaltrial Phase	Current Development Phase	Approved/Unapproved	Patent Expiry	Prediction Of Launch	Outcome measures	Sponsor/Collaborator	Primary Sponsor	Sponsor Type	Sponsor Classification	Licensing Deal	Historical Sales Data	Odd/Fta/Bta	Contact Detail	Contact Name	Designation	Contact Email	Contact Number	Contact Address	Gender	Age	Population Size	Study Design	Study Type	First Posted	Results First Posted	Last Update Posted	Location

Country/Continent	Trial Id	Start Date	Acronym	Study Title	Product Name	Primary Product	Synonym	Product Type	Biological Subtype	Industry Type	Biomarker/Moa	Disease/Indication	Therapeutic Area	Trial Status	Terminated Reason	Completion Date	Originaltrial Phase	Current Development Phase	Approved/Unapproved	Patent Expiry	Prediction Of Launch	Outcome measures	Sponsor/Collaborator	Primary Sponsor	Sponsor Type	Sponsor Classification	Licensing Deal	Historical Sales Data	Odd/Fta/Bta	Contact Detail	Contact Name	Designation	Contact Email	Contact Number	Contact Address	Gender	Age	Population Size	Study Design	Study Type	First Posted	Results First Posted	Last Update Posted	Location
Europe	2021-003900-42	2022-07-15	Subscribe Clival For more info	A Phase 3B, Multicenter, Randomized, Double-Blind Extension Study To Evaluate The Continued Efficacy And Safety Of Oral Edaravone Administered For An Additional Period Of Up To 48 Weeks Following Study Mt-1186-A02 In Subjects With Amyotrophic Lateral Scle	Edaravone	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Antioxidant Action	Amyotrophic Lateral Sclerosis	Subscribe Clival For more info	DE(Ongoing) IT(Ongoing)	Subscribe Clival For more info	--	Phase 3	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For More Info	--	Mitsubishi Tanabe Pharma Development America Inc (Mtda)	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Subscribe Clival For more info	Male, Female	0	0	--	Interventional	--	--	--	Subscribe Clival For more info

Showing 1 to 1 of 1 entries

Previous1Next

Mitsubishi Tanabe Pharma Development America Inc Europe

Advance Filter

Last Update : 2005 To Apr 2023

Cookies & Privacy

Select cookies to accept